| pubmed-article:17291217 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0021344 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0037284 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0205276 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:17291217 | lifeskim:mentions | umls-concept:C0286079 | lld:lifeskim |
| pubmed-article:17291217 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17291217 | pubmed:dateCreated | 2007-2-12 | lld:pubmed |
| pubmed-article:17291217 | pubmed:abstractText | Human papilloma virus (HPV)-associated diseases are increasingly diagnosed in solid organ recipients. Cidofovir (CDV) is a broad-spectrum antiviral agent with activity against all human herpes viruses and HPV. From 2000-2004, a total of 1303 solid organ transplants (SOT) were performed at our center. Six transplant recipients were treated with topical CDV for HPV-associated lesions. One cardiac recipient responded to a single injection of CDV into his recurrent anal condylomata. In a renal recipient with recurrent penile condylomata CDV was injected into the lesions four times (2 week interval) until lesions regressed. One renal recipient developed multiple vaginal and anal intradermal neoplasias, which relapsed after laser ablation. The lesions were repeatedly injected with CDV and completely disappeared. Two renal recipients with widespread verrucae vulgares were treated with CDV gel, which resulted in regression of the lesions. One patient developed donor derived verrucae vulgares on both transplanted hands, which responded to CDV gel. Four of the six patients were switched from calcineurin inhibitors (CNIs) to Sirolimus (SIR). CDV was found effective in the treatment of HPV-associated skin lesions in SOT recipients. It needs to be determined whether switch from CNIs to SIR might have contributed to the beneficial effect of CDV. | lld:pubmed |
| pubmed-article:17291217 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17291217 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17291217 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17291217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17291217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17291217 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17291217 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17291217 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:17291217 | pubmed:issn | 0934-0874 | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:SchneebergerS... | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:MargreiterRai... | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:LarcherClaraC | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:AignerFelixF | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:BonattiHugoH | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:BoesmuellerCl... | lld:pubmed |
| pubmed-article:17291217 | pubmed:author | pubmed-author:Widschwendner... | lld:pubmed |
| pubmed-article:17291217 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17291217 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:17291217 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17291217 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17291217 | pubmed:pagination | 238-46 | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:meshHeading | pubmed-meshheading:17291217... | lld:pubmed |
| pubmed-article:17291217 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17291217 | pubmed:articleTitle | Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. | lld:pubmed |
| pubmed-article:17291217 | pubmed:affiliation | Department of General and Transplant Surgery, Innsbruck, Austria. hugo.bonatti@uklibk.ac.at | lld:pubmed |
| pubmed-article:17291217 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17291217 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:17291217 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17291217 | lld:pubmed |
